首页 > 最新文献

Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine最新文献

英文 中文
Efficacy of Veno-Arterial Extracorporeal Life Support in Adult Patients with Refractory Cardiogenic Shock. 静脉-动脉体外生命支持在成人难治性心源性休克患者中的疗效。
IF 2 Q4 RESPIRATORY SYSTEM Pub Date : 2022-07-21 eCollection Date: 2022-01-01 DOI: 10.1177/11795484221113988
E R Kurniawati, Smj van Kuijk, Npa Vranken, J G Maessen, P W Weerwind

Background: This study aimed to describe the efficacy of veno-arterial extracorporeal life support (VA-ECLS) through early lactate clearance and pH restoration and assess the potential association with 30-day survival following hospital discharge.

Methods: Data of patients receiving VA-ECLS for at least 24 h were retrospectively compiled. Blood lactate levels, liver enzymes, and kidney parameters prior to VA-ECLS initiation and at 2, 8, 14, 20, and 26 h of support had been recorded as part of clinical care. The primary outcome was 30-day survival.

Results: Of 77 patients who underwent VA-ECLS for refractory cardiogenic shock, 44.2% survived. For all non-survivors, ECLS was initiated after eight hours (p = .008). Blood pH was significantly higher in survivors compared to non-survivors at all time points except for pre-ECLS. Lactate levels were significantly lower in survivors (median range 1.95-4.70 vs 2.90-6.70 mmol/L for survivors vs non-survivors, respectively). Univariate and multivariate analyses indicated that blood pH at 24 h (OR 0.045, 95% CI: 0.005-0.448 for pH <7.35, p = .045) and lactate concentration pre-ECLS (OR 0.743, 95% CI: 0.590-0.936, p = .012) were reliable predictors for 30-day survival. Further, ischemic cardiogenic shock as ECLS indication showed 36.2% less lactate clearance compared to patients with other indications such as arrhythmia, postcardiotomy, and ECPR.

Conclusion: ECLS showed to be an effective treatment in reducing blood lactate levels in patients suffering from refractory cardiogenic shock in which the outcome is influenced by the initial lactate level and pH in the early phase of the intervention.

背景:本研究旨在通过早期乳酸清除和pH恢复来描述静脉-动脉体外生命支持(VA-ECLS)的疗效,并评估其与出院后30天生存率的潜在关联。方法:回顾性整理接受VA-ECLS治疗至少24小时的患者资料。作为临床护理的一部分,记录VA-ECLS开始前和支持后2、8、14、20和26小时的血乳酸水平、肝酶和肾脏参数。主要终点为30天生存率。结果:77例难治性心源性休克患者行VA-ECLS, 44.2%存活。对于所有非幸存者,ECLS在8小时后开始(p = 0.008)。在除ecls前外的所有时间点,幸存者的血液pH值明显高于非幸存者。幸存者的乳酸水平明显较低(中位范围分别为1.95-4.70 mmol/L和2.90-6.70 mmol/L)。单因素和多因素分析表明,24小时血pH值(OR 0.045, 95% CI: 0.005-0.448, pH p = 0.045)和ecls前乳酸浓度(OR 0.743, 95% CI: 0.590-0.936, p = 0.012)是30天生存率的可靠预测因子。此外,缺血性心源性休克作为ECLS指征的乳酸清除率比其他指征(如心律失常、心脏切开术和ECPR)的患者低36.2%。结论:ECLS是降低难治性心源性休克患者血乳酸水平的有效治疗方法,其预后受干预早期初始乳酸水平和pH值的影响。
{"title":"Efficacy of Veno-Arterial Extracorporeal Life Support in Adult Patients with Refractory Cardiogenic Shock.","authors":"E R Kurniawati,&nbsp;Smj van Kuijk,&nbsp;Npa Vranken,&nbsp;J G Maessen,&nbsp;P W Weerwind","doi":"10.1177/11795484221113988","DOIUrl":"https://doi.org/10.1177/11795484221113988","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to describe the efficacy of veno-arterial extracorporeal life support (VA-ECLS) through early lactate clearance and pH restoration and assess the potential association with 30-day survival following hospital discharge.</p><p><strong>Methods: </strong>Data of patients receiving VA-ECLS for at least 24 h were retrospectively compiled. Blood lactate levels, liver enzymes, and kidney parameters prior to VA-ECLS initiation and at 2, 8, 14, 20, and 26 h of support had been recorded as part of clinical care. The primary outcome was 30-day survival.</p><p><strong>Results: </strong>Of 77 patients who underwent VA-ECLS for refractory cardiogenic shock, 44.2% survived. For all non-survivors, ECLS was initiated after eight hours (<i>p</i> = .008). Blood pH was significantly higher in survivors compared to non-survivors at all time points except for pre-ECLS. Lactate levels were significantly lower in survivors (median range 1.95-4.70 vs 2.90-6.70 mmol/L for survivors vs non-survivors, respectively). Univariate and multivariate analyses indicated that blood pH at 24 h (OR 0.045, 95% CI: 0.005-0.448 for pH <7.35, <i>p</i> = .045) and lactate concentration pre-ECLS (OR 0.743, 95% CI: 0.590-0.936, <i>p</i> = .012) were reliable predictors for 30-day survival. Further, ischemic cardiogenic shock as ECLS indication showed 36.2% less lactate clearance compared to patients with other indications such as arrhythmia, postcardiotomy, and ECPR.</p><p><strong>Conclusion: </strong>ECLS showed to be an effective treatment in reducing blood lactate levels in patients suffering from refractory cardiogenic shock in which the outcome is influenced by the initial lactate level and pH in the early phase of the intervention.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":" ","pages":"11795484221113988"},"PeriodicalIF":2.0,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40639966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 with Rapid Progression to Hypoxemia Likely due to Imbalance between Ventilation and Blood Flow: A Case Report. COVID-19快速发展为低氧血症可能是由于通气和血流不平衡:1例报告。
IF 2 Q4 RESPIRATORY SYSTEM Pub Date : 2022-02-04 eCollection Date: 2022-01-01 DOI: 10.1177/11795484211073273
Nobuyuki Koriyama, Akihiro Moriuchi, Kensaku Higashi, Tetsuro Kataoka, Takuro Arimizu, Go Takaguchi, Hideki Matsuoka, Maki Otsuka

Background: In COVID-19 pneumonia, cases of severe hypoxemia in the early stage and cases of sudden deterioration in respiratory status due to silent hypoxia leading to death, have been reported.

Case summary: A 70-year-old Japanese man with essential hypertension, dyslipidemia, chronic kidney disease and emphysema was hospitalized with the novel coronavirus disease. He had hypoxemia that was disproportionate to the severity of pneumonia indicated by computed tomography (CT), along with coagulation abnormalities. We speculated that there was a high possibility that he had developed ventilation and blood flow imbalance due to pulmonary intravascular coagulopathy (PIC) or hypoxic pulmonary vasoconstriction (HPV). In this case, early, short-term combination therapy with remdesivir, nafamostat mesylate and low-dose dexamethasone (Dex) was successful.

Conclusion: In COVID-19 patients with multiple comorbidities who have hypoxemia and coagulation abnormalities that are disproportionate to the severity of pneumonia on CT, it is important to commence antiviral and anticoagulant therapy as soon as possible, followed by use of a low dose of Dex.

背景:在COVID-19肺炎中,已经报道了早期严重低氧血症和由于无症状缺氧导致呼吸状态突然恶化导致死亡的病例。病例总结:一名70岁的日本男性,患有原发性高血压、血脂异常、慢性肾病和肺气肿,因新型冠状病毒病住院治疗。他有低氧血症,与计算机断层扫描(CT)显示的肺炎严重程度不成比例,并伴有凝血异常。我们推测,由于肺血管内凝血功能障碍(PIC)或缺氧性肺血管收缩(HPV),他很可能出现了通气和血流不平衡。在这种情况下,早期,短期联合治疗瑞德西韦,甲磺酸那莫他酯和低剂量地塞米松(Dex)是成功的。结论:对于具有多种合并症的COVID-19患者,如果CT显示低氧血症和凝血异常与肺炎严重程度不成比例,应尽早开始抗病毒和抗凝治疗,然后使用低剂量的右美托昔单抗。
{"title":"COVID-19 with Rapid Progression to Hypoxemia Likely due to Imbalance between Ventilation and Blood Flow: A Case Report.","authors":"Nobuyuki Koriyama,&nbsp;Akihiro Moriuchi,&nbsp;Kensaku Higashi,&nbsp;Tetsuro Kataoka,&nbsp;Takuro Arimizu,&nbsp;Go Takaguchi,&nbsp;Hideki Matsuoka,&nbsp;Maki Otsuka","doi":"10.1177/11795484211073273","DOIUrl":"https://doi.org/10.1177/11795484211073273","url":null,"abstract":"<p><strong>Background: </strong>In COVID-19 pneumonia, cases of severe hypoxemia in the early stage and cases of sudden deterioration in respiratory status due to silent hypoxia leading to death, have been reported.</p><p><strong>Case summary: </strong>A 70-year-old Japanese man with essential hypertension, dyslipidemia, chronic kidney disease and emphysema was hospitalized with the novel coronavirus disease. He had hypoxemia that was disproportionate to the severity of pneumonia indicated by computed tomography (CT), along with coagulation abnormalities. We speculated that there was a high possibility that he had developed ventilation and blood flow imbalance due to pulmonary intravascular coagulopathy (PIC) or hypoxic pulmonary vasoconstriction (HPV). In this case, early, short-term combination therapy with remdesivir, nafamostat mesylate and low-dose dexamethasone (Dex) was successful.</p><p><strong>Conclusion: </strong>In COVID-19 patients with multiple comorbidities who have hypoxemia and coagulation abnormalities that are disproportionate to the severity of pneumonia on CT, it is important to commence antiviral and anticoagulant therapy as soon as possible, followed by use of a low dose of Dex.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":" ","pages":"11795484211073273"},"PeriodicalIF":2.0,"publicationDate":"2022-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/c7/10.1177_11795484211073273.PMC8819745.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39766444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
A Case of Complex Pulmonary Hypertension: the Importance of Diagnostic Investigation. 1例复杂肺动脉高压:诊断调查的重要性。
IF 2 Q4 RESPIRATORY SYSTEM Pub Date : 2022-01-08 eCollection Date: 2022-01-01 DOI: 10.1177/11795484211073292
Aninka Saboe, Vani Marindani, Charlotte Johanna Cool, Hilman Syawaluddin, Hussein S Kartamihardja, Prayudi Santoso, Mohammad Rizki Akbar

Pulmonary hypertension (PH) encompasses several heterogeneous groups of multiple diseases characterized by abnormal pulmonary arterial blood pressure elevation. Unrepaired atrial septal defect (ASD) may be associated with pulmonary arterial hypertension (PAH), indicating pulmonary vascular remodeling. Furthermore, unrepaired ASD could also be associated with other conditions, such as left heart disease or thromboembolism, contributing to the disease progression. We present a case of a 61-years-old woman with complex PH comprising several etiologies, which are PAH due to unrepaired Secundum ASD, mitral regurgitation caused by mitral valve prolapse as a group 2 PH, pulmonary embolism (PE) which progress to chronic thromboembolism PH (CTEPH) and post-acute sequelae of SARS Cov-2. We highlighted the importance of diagnostic investigation in PH, which is crucial to avoid misdiagnosis and inappropriate treatment that could be detrimental for the patient.

肺动脉高压(PH)包括以肺动脉血压异常升高为特征的几种异质性多种疾病。未修复的房间隔缺损(ASD)可能与肺动脉高压(PAH)相关,表明肺血管重构。此外,未修复的ASD也可能与其他疾病有关,如左心疾病或血栓栓塞,导致疾病进展。我们报告了一例61岁女性的复杂PH,包括多种病因,包括未修复的继发性ASD引起的PAH,二尖瓣脱垂引起的二尖瓣反流(2组PH),肺栓塞(PE)进展为慢性血栓栓塞性PH (CTEPH)和SARS Cov-2急性后后遗症。我们强调了PH诊断调查的重要性,这对于避免可能对患者有害的误诊和不适当的治疗至关重要。
{"title":"A Case of Complex Pulmonary Hypertension: the Importance of Diagnostic Investigation.","authors":"Aninka Saboe,&nbsp;Vani Marindani,&nbsp;Charlotte Johanna Cool,&nbsp;Hilman Syawaluddin,&nbsp;Hussein S Kartamihardja,&nbsp;Prayudi Santoso,&nbsp;Mohammad Rizki Akbar","doi":"10.1177/11795484211073292","DOIUrl":"https://doi.org/10.1177/11795484211073292","url":null,"abstract":"<p><p>Pulmonary hypertension (PH) encompasses several heterogeneous groups of multiple diseases characterized by abnormal pulmonary arterial blood pressure elevation. Unrepaired atrial septal defect (ASD) may be associated with pulmonary arterial hypertension (PAH), indicating pulmonary vascular remodeling. Furthermore, unrepaired ASD could also be associated with other conditions, such as left heart disease or thromboembolism, contributing to the disease progression. We present a case of a 61-years-old woman with complex PH comprising several etiologies, which are PAH due to unrepaired Secundum ASD, mitral regurgitation caused by mitral valve prolapse as a group 2 PH, pulmonary embolism (PE) which progress to chronic thromboembolism PH (CTEPH) and post-acute sequelae of SARS Cov-2. We highlighted the importance of diagnostic investigation in PH, which is crucial to avoid misdiagnosis and inappropriate treatment that could be detrimental for the patient.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":" ","pages":"11795484211073292"},"PeriodicalIF":2.0,"publicationDate":"2022-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e4/40/10.1177_11795484211073292.PMC8744089.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39818172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe and Apparently Irreversible Pulmonary Arterial Hypertension in a Patient with Ostium Secundum Atrial Septal Defect - A Successful Case of Treat and Close Strategy. 严重且明显不可逆的肺动脉高压合并第二口房间隔缺损-一例成功的治疗和闭合策略。
IF 2 Q4 RESPIRATORY SYSTEM Pub Date : 2022-01-01 DOI: 10.1177/11795484221141298
Alexandra Briosa, Filipa Ferreira, João Santos, Sofia Alegria, Maria José Loureiro, Débora Repolho, Hélder Pereira

Irreversible pulmonary arterial hypertension is considered a contraindication for surgical or percutaneous closure of atrial septal defects (ASD) due to risk of right heart failure. We present a case of 37 years-old woman who was referred to our center due to progressive worsening fatigue and high probability of pulmonary hypertension on a transthoracic echocardiogram. The diagnostic work-up revealed the presence of an ostium secundum atrial septal defect and severe pre-capillary pulmonary hypertension on right heart cathetherization (RHC). The patient was considered inoperable and started medical therapy with sildenafil and bosentan. After one year of treatment, she repeated RHC that showed a significant reduction in pulmonary vascular resistance making her eligible for closure. Surgical closure of ASD with a fenestra was performed with success. Our case emphasizes the importance of individual assessment even if cases where initial evaluation is unfavorable to closure in accordance with the guidelines.

由于右心衰竭的风险,不可逆肺动脉高压被认为是手术或经皮房间隔缺损(ASD)闭合术的禁忌症。我们报告一个37岁的女性病例,她在经胸超声心动图上因逐渐恶化的疲劳和高概率的肺动脉高压而被转介到我们的中心。诊断检查显示右心导管(RHC)存在第二口房间隔缺损和严重的毛细血管前肺动脉高压。患者被认为不能手术,并开始使用西地那非和波生坦进行药物治疗。治疗一年后,患者再次行RHC,结果显示肺血管阻力明显降低,符合手术条件。手术封闭的ASD与窗是成功的。我们的案例强调了个人评估的重要性,即使最初的评估不利于按照指导方针结束。
{"title":"Severe and Apparently Irreversible Pulmonary Arterial Hypertension in a Patient with Ostium Secundum Atrial Septal Defect - A Successful Case of Treat and Close Strategy.","authors":"Alexandra Briosa,&nbsp;Filipa Ferreira,&nbsp;João Santos,&nbsp;Sofia Alegria,&nbsp;Maria José Loureiro,&nbsp;Débora Repolho,&nbsp;Hélder Pereira","doi":"10.1177/11795484221141298","DOIUrl":"https://doi.org/10.1177/11795484221141298","url":null,"abstract":"<p><p>Irreversible pulmonary arterial hypertension is considered a contraindication for surgical or percutaneous closure of atrial septal defects (ASD) due to risk of right heart failure. We present a case of 37 years-old woman who was referred to our center due to progressive worsening fatigue and high probability of pulmonary hypertension on a transthoracic echocardiogram. The diagnostic work-up revealed the presence of an ostium secundum atrial septal defect and severe pre-capillary pulmonary hypertension on right heart cathetherization (RHC). The patient was considered inoperable and started medical therapy with sildenafil and bosentan. After one year of treatment, she repeated RHC that showed a significant reduction in pulmonary vascular resistance making her eligible for closure. Surgical closure of ASD with a fenestra was performed with success. Our case emphasizes the importance of individual assessment even if cases where initial evaluation is unfavorable to closure in accordance with the guidelines.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"16 ","pages":"11795484221141298"},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6c/55/10.1177_11795484221141298.PMC9749546.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10405431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune Response to SARS-CoV-2 Vaccine among Heart Transplant Recipients: A Systematic Review 心脏移植受者对SARS-CoV-2疫苗的免疫反应:一项系统综述
IF 2 Q4 RESPIRATORY SYSTEM Pub Date : 2022-01-01 DOI: 10.1177/11795484221105327
Saeed Shoar, Adriana C. Carolina Prada-Ruiz, Gabriel Patarroyo-Aponte, A. Chaudhary, Mohammad Sadegh Asadi
Background Heart transplant (HTX) recipients are at a significantly higher risk of adverse clinical outcomes, due to chronic immunosuppression and co-existence of other chronic conditions, when contracting the SARS-CoV-2 infection. Although vaccination against SARS-CoV-2 is currently the most promising measure for the prevention of severe Coronavirus Disease 2019 (COVID-19) among solid organ transplant recipients, the extent of immune response and its protective efficacy among patients receiving HTX has not been sufficiently studied. Methods We performed a systematic review of the literature by inquiring PubMed/Medline to identify original studies among HTX recipients, who had received at least one dose of the SARS-CoV-2 vaccine. Data on the measured humoral or cellular immune response was collected from all the eligible studies. Factors associated with a poor immune response were further investigated within these studies. Results A total of 12 studies comprising 563 HTX recipients were included. The average age of the study participants was 60.8 years. Sixty four percent of the study population were male. Ninety percent of the patients had received an mRNA vaccine (Pfizer/ BNT162b2 or Moderna/mRNA-1273). A positive immune response to SARS-CoV-2 vaccine was variably reported in 0% to 100% of the patients. Older age (> 65 years), vaccine dose (first, second, or third), time since HTX to the first dose of the vaccine, the time interval between the latest dose of the vaccine and measurement of the immune response, and the type of immunosuppressive regimen were all indicated as potential determinants of a robust immune response to the SARS-CoV-2 vaccination. Conclusion HTX recipients demonstrate a weaker immune response to the vaccination against SARS-CoV-2 compared to the general population. Older age, anti-metabolite agents such as mycophenolate mofetil, and vaccination during the first year following the HTX have been indicated as potential determinants of a poor immune response.
背景心脏移植(HTX)受者在感染SARS-CoV-2时,由于慢性免疫抑制和其他慢性疾病的共存,不良临床结果的风险明显更高。虽然针对SARS-CoV-2的疫苗接种是目前在实体器官移植受者中预防2019年严重冠状病毒病(COVID-19)最有希望的措施,但HTX患者的免疫反应程度及其保护效果尚未得到充分研究。方法通过查询PubMed/Medline对文献进行系统回顾,以确定在至少接受过一剂SARS-CoV-2疫苗的HTX接受者中进行的原始研究。从所有符合条件的研究中收集体液或细胞免疫反应的测量数据。在这些研究中进一步调查了与免疫反应不良相关的因素。结果共纳入12项研究,563名HTX受者。研究参与者的平均年龄为60.8岁。64%的研究对象为男性。90%的患者接受了mRNA疫苗(Pfizer/ BNT162b2或Moderna/mRNA-1273)。0%至100%的患者报告了对SARS-CoV-2疫苗的阳性免疫反应。年龄(> 65岁)、疫苗剂量(第一次、第二次或第三次)、从HTX到第一次接种疫苗的时间、最近一次接种疫苗与免疫反应测量之间的时间间隔以及免疫抑制方案的类型都被认为是对SARS-CoV-2疫苗接种产生强大免疫反应的潜在决定因素。结论与普通人群相比,HTX受者对SARS-CoV-2疫苗的免疫反应较弱。年龄较大,抗代谢物药物如霉酚酸酯,以及HTX后第一年接种疫苗已被认为是不良免疫反应的潜在决定因素。
{"title":"Immune Response to SARS-CoV-2 Vaccine among Heart Transplant Recipients: A Systematic Review","authors":"Saeed Shoar, Adriana C. Carolina Prada-Ruiz, Gabriel Patarroyo-Aponte, A. Chaudhary, Mohammad Sadegh Asadi","doi":"10.1177/11795484221105327","DOIUrl":"https://doi.org/10.1177/11795484221105327","url":null,"abstract":"Background Heart transplant (HTX) recipients are at a significantly higher risk of adverse clinical outcomes, due to chronic immunosuppression and co-existence of other chronic conditions, when contracting the SARS-CoV-2 infection. Although vaccination against SARS-CoV-2 is currently the most promising measure for the prevention of severe Coronavirus Disease 2019 (COVID-19) among solid organ transplant recipients, the extent of immune response and its protective efficacy among patients receiving HTX has not been sufficiently studied. Methods We performed a systematic review of the literature by inquiring PubMed/Medline to identify original studies among HTX recipients, who had received at least one dose of the SARS-CoV-2 vaccine. Data on the measured humoral or cellular immune response was collected from all the eligible studies. Factors associated with a poor immune response were further investigated within these studies. Results A total of 12 studies comprising 563 HTX recipients were included. The average age of the study participants was 60.8 years. Sixty four percent of the study population were male. Ninety percent of the patients had received an mRNA vaccine (Pfizer/ BNT162b2 or Moderna/mRNA-1273). A positive immune response to SARS-CoV-2 vaccine was variably reported in 0% to 100% of the patients. Older age (> 65 years), vaccine dose (first, second, or third), time since HTX to the first dose of the vaccine, the time interval between the latest dose of the vaccine and measurement of the immune response, and the type of immunosuppressive regimen were all indicated as potential determinants of a robust immune response to the SARS-CoV-2 vaccination. Conclusion HTX recipients demonstrate a weaker immune response to the vaccination against SARS-CoV-2 compared to the general population. Older age, anti-metabolite agents such as mycophenolate mofetil, and vaccination during the first year following the HTX have been indicated as potential determinants of a poor immune response.","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"1 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83082383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Relationships of Walking and non-Walking Physical Activities in Daily Life with Cognitive Function and Physical Characteristics in Male Patients with Mild Chronic Obstructive Pulmonary Disease. 男性轻度慢性阻塞性肺疾病患者日常步行和非步行运动与认知功能和身体特征的关系
IF 2 Q4 RESPIRATORY SYSTEM Pub Date : 2022-01-01 DOI: 10.1177/11795484221146374
Shojiro Egoshi, Jun Horie, Akinori Nakagawa, Yuriko Matsunaga, Shinichiro Hayashi

Background: Chronic obstructive pulmonary disease (COPD) is accompanied by dyspnea on exertion due to airflow limitation caused by bronchial stenosis, with afflicted patients being less physically active. Therefore, physical activity is important for disease management.

Objectives: This study aimed to examine the relationships of walking and non-walking physical activities with cognitive function or physical characteristics of patients with mild COPD in a community without respiratory rehabilitation.

Design: Cross-sectional study.

Data sources and methods: We included 40 male patients (mean age, 75.7 ± 6.7 years) with stable mild COPD. A three-axis accelerometer was used to evaluate walking and non-walking physical activities in daily life. Cognition, respiratory function, skeletal muscle mass, limb muscle strength, exercise capacity, and health-related quality of life were assessed.

Results: Regarding daily exercise amount (metabolic equivalents × hours; Ex), 87.5% of the participants had walking activities of 0-2 Ex, while 67.5% had non-walking activities of 1-3 Ex. Walking activity was significantly correlated with cognitive function (P < .05), walking distance (P < .01), and health-related quality of life (P < .05), but not with muscle mass. However, non-walking activity was significantly correlated with the body mass index (P < .05), muscle mass (P < .05), and walking distance (P < .01), but not with cognitive function. Moreover, the relationship between non-walking activity and health-related quality of life was weaker than the corresponding relationship with walking activity.

Conclusion: In patients with mild COPD, walking and non-walking physical activities showed different relationships with cognitive function and physical characteristics. The findings suggest that self-management of such patients requires maintenance of both walking and non-walking activities in a balanced manner.

背景:慢性阻塞性肺疾病(COPD)是由于支气管狭窄引起的气流限制而伴有运动时呼吸困难,患者体力活动较少。因此,体育活动对疾病管理很重要。目的:本研究旨在探讨在没有呼吸康复的社区中,步行和非步行体力活动与轻度COPD患者认知功能或身体特征的关系。设计:横断面研究。数据来源和方法:我们纳入40例男性稳定期轻度COPD患者(平均年龄75.7±6.7岁)。使用三轴加速度计评估日常生活中步行和非步行的身体活动。评估认知、呼吸功能、骨骼肌质量、肢体肌肉力量、运动能力和健康相关生活质量。结果:关于每日运动量(代谢当量×小时;87.5%的参与者有0-2 Ex的步行活动,67.5%的参与者有1-3 Ex的非步行活动。步行活动与认知功能显著相关(P P P P P P P P结论:轻度COPD患者步行和非步行体力活动与认知功能和身体特征的关系不同。研究结果表明,这些患者的自我管理需要以平衡的方式维持步行和非步行活动。
{"title":"Relationships of Walking and non-Walking Physical Activities in Daily Life with Cognitive Function and Physical Characteristics in Male Patients with Mild Chronic Obstructive Pulmonary Disease.","authors":"Shojiro Egoshi,&nbsp;Jun Horie,&nbsp;Akinori Nakagawa,&nbsp;Yuriko Matsunaga,&nbsp;Shinichiro Hayashi","doi":"10.1177/11795484221146374","DOIUrl":"https://doi.org/10.1177/11795484221146374","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is accompanied by dyspnea on exertion due to airflow limitation caused by bronchial stenosis, with afflicted patients being less physically active. Therefore, physical activity is important for disease management.</p><p><strong>Objectives: </strong>This study aimed to examine the relationships of walking and non-walking physical activities with cognitive function or physical characteristics of patients with mild COPD in a community without respiratory rehabilitation.</p><p><strong>Design: </strong>Cross-sectional study.</p><p><strong>Data sources and methods: </strong>We included 40 male patients (mean age, 75.7 ± 6.7 years) with stable mild COPD. A three-axis accelerometer was used to evaluate walking and non-walking physical activities in daily life. Cognition, respiratory function, skeletal muscle mass, limb muscle strength, exercise capacity, and health-related quality of life were assessed.</p><p><strong>Results: </strong>Regarding daily exercise amount (metabolic equivalents × hours; Ex), 87.5% of the participants had walking activities of 0-2 Ex, while 67.5% had non-walking activities of 1-3 Ex. Walking activity was significantly correlated with cognitive function (<i>P</i> < .05), walking distance (<i>P</i> < .01), and health-related quality of life (<i>P</i> < .05), but not with muscle mass. However, non-walking activity was significantly correlated with the body mass index (<i>P</i> < .05), muscle mass (<i>P</i> < .05), and walking distance (<i>P</i> < .01), but not with cognitive function. Moreover, the relationship between non-walking activity and health-related quality of life was weaker than the corresponding relationship with walking activity.</p><p><strong>Conclusion: </strong>In patients with mild COPD, walking and non-walking physical activities showed different relationships with cognitive function and physical characteristics. The findings suggest that self-management of such patients requires maintenance of both walking and non-walking activities in a balanced manner.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"16 ","pages":"11795484221146374"},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5f/ec/10.1177_11795484221146374.PMC9791294.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10453376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complicated Case of Multidrug-Resistant Tuberculosis with Multiple Comorbidities, Successfully Treated After Several Treatment Modifications. 多药耐药结核病合并多种合并症的复杂病例,经多次修改治疗成功。
IF 2 Q4 RESPIRATORY SYSTEM Pub Date : 2022-01-01 DOI: 10.1177/11795484221142468
Benedreky Leo, Heni Retnowulan

A 59-year-old man with relapsed pulmonary TB developed rifampin resistance. He presented with chronic untreated hepatitis B, which developed into liver cirrhosis, type 2 diabetes with diabetic retinopathy, and osteoarthritis of right knee. His initial MDR regimen included levofloxacin, cycloserine, bedaquiline, linezolid, and high-dose isoniazid. He developed episodes of linezolid-induced myelosuppression, resulting in temporary discontinuation and dose reduction, and ultimately, substitution of linezolid. On the seventh month of treatment, he developed severe depression with visual hallucination, resulting in cycloserine dose reduction. We maintained the principle of at least 4 active drugs throughout his treatment. He was considered cured after 26 months of treatment.

一名患有复发性肺结核的59岁男性出现了利福平耐药性。他患有慢性未经治疗的乙型肝炎,后来发展为肝硬化、2型糖尿病合并糖尿病视网膜病变和右膝骨关节炎。他最初的耐多药治疗方案包括左氧氟沙星、环丝氨酸、贝达喹啉、利奈唑胺和大剂量异烟肼。他出现了利奈唑胺诱导的骨髓抑制发作,导致暂时停药和剂量减少,最终改用利奈唑胺。治疗第7个月,患者出现严重抑郁伴视幻觉,导致环丝氨酸剂量减少。在整个治疗过程中,我们坚持至少使用4种有效药物的原则。经过26个月的治疗,他被认为治愈了。
{"title":"Complicated Case of Multidrug-Resistant Tuberculosis with Multiple Comorbidities, Successfully Treated After Several Treatment Modifications.","authors":"Benedreky Leo,&nbsp;Heni Retnowulan","doi":"10.1177/11795484221142468","DOIUrl":"https://doi.org/10.1177/11795484221142468","url":null,"abstract":"<p><p>A 59-year-old man with relapsed pulmonary TB developed rifampin resistance. He presented with chronic untreated hepatitis B, which developed into liver cirrhosis, type 2 diabetes with diabetic retinopathy, and osteoarthritis of right knee. His initial MDR regimen included levofloxacin, cycloserine, bedaquiline, linezolid, and high-dose isoniazid. He developed episodes of linezolid-induced myelosuppression, resulting in temporary discontinuation and dose reduction, and ultimately, substitution of linezolid. On the seventh month of treatment, he developed severe depression with visual hallucination, resulting in cycloserine dose reduction. We maintained the principle of at least 4 active drugs throughout his treatment. He was considered cured after 26 months of treatment.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"16 ","pages":"11795484221142468"},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/b8/10.1177_11795484221142468.PMC9761204.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10424567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Erratum: Erratum. 错误:错误。
IF 2 Q4 RESPIRATORY SYSTEM Pub Date : 2022-01-01 DOI: 10.1177/11795484221127555
Rosie S Jones, Patricia S Smith, Paul H Berg, Amparo de la Peña, Paul P Cook, Imad Shawa, Kathleen M Kioussopoulos, Yu Hu, Robert J Schott

[This corrects the article DOI: 10.1177/11795484221119316.].

[这更正了文章DOI: 10.1177/11795484221119316.]。
{"title":"Erratum: Erratum.","authors":"Rosie S Jones,&nbsp;Patricia S Smith,&nbsp;Paul H Berg,&nbsp;Amparo de la Peña,&nbsp;Paul P Cook,&nbsp;Imad Shawa,&nbsp;Kathleen M Kioussopoulos,&nbsp;Yu Hu,&nbsp;Robert J Schott","doi":"10.1177/11795484221127555","DOIUrl":"https://doi.org/10.1177/11795484221127555","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/11795484221119316.].</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"16 ","pages":"11795484221127555"},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755543/pdf/10.1177_11795484221127555.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10405433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence, Presentation and Outcomes of Silent Hypoxemia in COVID-19 COVID-19无症状低氧血症的流行、表现和结局
IF 2 Q4 RESPIRATORY SYSTEM Pub Date : 2022-01-01 DOI: 10.1177/11795484221082761
Amélia Ribeiro, M. Mendonça, C. Sabina Sousa, M. Trigueiro Barbosa, M. Morais‐Almeida
Dyspnea is reported in a minority of patients affected by coronavirus disease 2019 (COVID-19). Even patients with pneumonia can present hypoxemia without any respiratory distress, a phenomenon known as “silent” or “happy hypoxemia”. During the current pandemic there were only a few studies conducted on this subject and these were quite heterogeneous. Therefore, the prevalence of “silent hypoxemia” varied substantially. While studies did not show a clear tendency of “silent hypoxemia” to poorer outcomes compared to hypoxemia presenting with dyspnea, several showed that patients with “silent hypoxemia” are not protected from poor outcomes either. There is a need for a uniform definition of “silent hypoxemia”, in order to better guide clinicians and investigators. More studies are needed to shed light on the mechanisms of “silent hypoxemia”, as well as its presentation and influence in the disease's progression and outcomes, so as to better assist physicians in the care of COVID-19 patients.
据报道,少数感染2019冠状病毒病(COVID-19)的患者存在呼吸困难。即使是肺炎患者也会出现低氧血症而没有任何呼吸窘迫,这种现象被称为“沉默”或“快乐低氧血症”。在目前的大流行期间,仅对这一主题进行了几项研究,而且这些研究相当不同。因此,“隐性低氧血症”的患病率差异很大。虽然研究没有明确显示“沉默性低氧血症”与以呼吸困难为表现的低氧血症相比有更差的预后倾向,但一些研究表明,“沉默性低氧血症”患者也不能避免不良预后。为了更好地指导临床医生和研究者,有必要对“隐性低氧血症”进行统一的定义。需要更多的研究来阐明“隐性低氧血症”的机制,以及它在疾病进展和结局中的表现和影响,以便更好地协助医生护理COVID-19患者。
{"title":"Prevalence, Presentation and Outcomes of Silent Hypoxemia in COVID-19","authors":"Amélia Ribeiro, M. Mendonça, C. Sabina Sousa, M. Trigueiro Barbosa, M. Morais‐Almeida","doi":"10.1177/11795484221082761","DOIUrl":"https://doi.org/10.1177/11795484221082761","url":null,"abstract":"Dyspnea is reported in a minority of patients affected by coronavirus disease 2019 (COVID-19). Even patients with pneumonia can present hypoxemia without any respiratory distress, a phenomenon known as “silent” or “happy hypoxemia”. During the current pandemic there were only a few studies conducted on this subject and these were quite heterogeneous. Therefore, the prevalence of “silent hypoxemia” varied substantially. While studies did not show a clear tendency of “silent hypoxemia” to poorer outcomes compared to hypoxemia presenting with dyspnea, several showed that patients with “silent hypoxemia” are not protected from poor outcomes either. There is a need for a uniform definition of “silent hypoxemia”, in order to better guide clinicians and investigators. More studies are needed to shed light on the mechanisms of “silent hypoxemia”, as well as its presentation and influence in the disease's progression and outcomes, so as to better assist physicians in the care of COVID-19 patients.","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"46 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86700533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Evaluation of Blood Biochemistry and Cardiopulmonary status of Hospitalized Covid-19 Patients in 3 Months Post Discharged Follow up Survey. 新冠肺炎住院患者出院后3个月血液生化及心肺状况随访调查
IF 2 Q4 RESPIRATORY SYSTEM Pub Date : 2022-01-01 DOI: 10.1177/11795484221119332
Saeed Nateghi, Elahe Hesari, Fariba Mansouri, Majid Akrami, Mandana Pourian, Arezoo Khosravani, Fatemeh Taghizadeh, Samaneh Akbarpour, Neda Faraji

Background: The new coronavirus causes systemic inflammation and damage to various organs. So, this study aimed to follow up patients with COVID -19 after recovery for three months by performing cardiac, pulmonary and laboratory tests.

Materials and methods: This was a prospective cohort study of COVID-19 patients who were discharged from Baharloo Hospital. The diagnosis of COVID-19 was confirmed by PCR or long CT scan. Inclusion criteria were age over 18 years and patients with more than 50% of pulmonary involvement in lung CT scan. The patients were called to Baharloo hospital three months after recovery and were examined for cardiac, pulmonary and blood tests.

Result: Our study included 178 participants with mean age of 55.70, and 50.6% of them were male. Among pulmonary factors in the hospital, 71.9%, 15.7%,1.7%,19.1% and 53.4% had positive GGO, consolidation, reverse halo sign, traction bronchiectasis and vascular enlargement, respectively. After three months follow up, percentage of patients who had reticulation, honeycombing, fibrotic brand and bullae were 12%, 1.1%,8.4% and 0%, respectively. The Mean values of FVC and FEV1 were reported 4.21 and 3.01, respectively. Among Cardiac factors, positive PVC, PAC and mean Pap were decreased after three months. Only Growth in myalgia and Decreased sense of taste were statistically significant. Also, D dimer, UA protein, PMN, Ferritin CRP, PMN, LDH and HB amounts had decreased significantly.

Conclusion: Our study indicated that in addition to pulmonary changes, rapid damage to other organs and the occurrence of cardiac symptoms and changes in laboratory result were also reported in patients recovered from COVID-19.

背景:新型冠状病毒可引起全身炎症和多器官损伤。因此,本研究旨在通过心脏、肺和实验室检查对康复后的COVID -19患者进行为期三个月的随访。材料和方法:本研究是一项前瞻性队列研究,对象是巴哈卢医院出院的COVID-19患者。通过PCR或长时间CT扫描确诊COVID-19。纳入标准为年龄大于18岁,肺部CT扫描累及50%以上的患者。这些病人在康复三个月后被叫到巴哈卢医院,接受了心脏、肺部和血液检查。结果:共纳入受试者178例,平均年龄55.70岁,男性占50.6%。院内肺因子中,GGO阳性占71.9%、15.7%、1.7%、19.1%、53.4%,实变、逆晕征、牵引支气管扩张、血管扩张。随访3个月后,出现网状、蜂窝、纤维化烙印和大疱的比例分别为12%、1.1%、8.4%和0%。FVC和FEV1平均值分别为4.21和3.01。在心脏因素中,3个月后,阳性的PVC、PAC和平均Pap下降。只有肌痛的增长和味觉的下降有统计学意义。D二聚体、UA蛋白、PMN、铁蛋白CRP、PMN、LDH、HB均显著降低。结论:我们的研究表明,COVID-19康复患者除了肺部改变外,还报告了其他器官的快速损害以及心脏症状的发生和实验室结果的改变。
{"title":"Evaluation of Blood Biochemistry and Cardiopulmonary status of Hospitalized Covid-19 Patients in 3 Months Post Discharged Follow up Survey.","authors":"Saeed Nateghi,&nbsp;Elahe Hesari,&nbsp;Fariba Mansouri,&nbsp;Majid Akrami,&nbsp;Mandana Pourian,&nbsp;Arezoo Khosravani,&nbsp;Fatemeh Taghizadeh,&nbsp;Samaneh Akbarpour,&nbsp;Neda Faraji","doi":"10.1177/11795484221119332","DOIUrl":"https://doi.org/10.1177/11795484221119332","url":null,"abstract":"<p><strong>Background: </strong>The new coronavirus causes systemic inflammation and damage to various organs. So, this study aimed to follow up patients with COVID -19 after recovery for three months by performing cardiac, pulmonary and laboratory tests.</p><p><strong>Materials and methods: </strong>This was a prospective cohort study of COVID-19 patients who were discharged from Baharloo Hospital. The diagnosis of COVID-19 was confirmed by PCR or long CT scan. Inclusion criteria were age over 18 years and patients with more than 50% of pulmonary involvement in lung CT scan. The patients were called to Baharloo hospital three months after recovery and were examined for cardiac, pulmonary and blood tests.</p><p><strong>Result: </strong>Our study included 178 participants with mean age of 55.70, and 50.6% of them were male. Among pulmonary factors in the hospital, 71.9%, 15.7%,1.7%,19.1% and 53.4% had positive GGO, consolidation, reverse halo sign, traction bronchiectasis and vascular enlargement, respectively. After three months follow up, percentage of patients who had reticulation, honeycombing, fibrotic brand and bullae were 12%, 1.1%,8.4% and 0%, respectively. The Mean values of FVC and FEV1 were reported 4.21 and 3.01, respectively. Among Cardiac factors, positive PVC, PAC and mean Pap were decreased after three months. Only Growth in myalgia and Decreased sense of taste were statistically significant. Also, D dimer, UA protein, PMN, Ferritin CRP, PMN, LDH and HB amounts had decreased significantly.</p><p><strong>Conclusion: </strong>Our study indicated that in addition to pulmonary changes, rapid damage to other organs and the occurrence of cardiac symptoms and changes in laboratory result were also reported in patients recovered from COVID-19.</p>","PeriodicalId":44269,"journal":{"name":"Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine","volume":"16 ","pages":"11795484221119332"},"PeriodicalIF":2.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/0c/10.1177_11795484221119332.PMC9791284.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9549752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1